Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Large Growth in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 1,663,760 shares, a growth of 458.4% from the November 30th total of 297,970 shares. Approximately 6.5% of the company’s shares are short sold. Based on an average daily volume of 7,431,668 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 7,431,668 shares, the days-to-cover ratio is currently 0.2 days. Approximately 6.5% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Armistice Capital LLC bought a new stake in shares of Senti Biosciences during the 2nd quarter valued at about $1,883,000. Nantahala Capital Management LLC bought a new stake in Senti Biosciences in the first quarter worth approximately $2,984,000. Heights Capital Management Inc. acquired a new position in Senti Biosciences in the first quarter valued at approximately $2,520,000. Geode Capital Management LLC boosted its holdings in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences during the 3rd quarter worth approximately $117,000. 25.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNTI has been the topic of several research reports. Leerink Partners started coverage on Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 price target on the stock. HC Wainwright started coverage on shares of Senti Biosciences in a research report on Tuesday, October 14th. They set a “buy” rating and a $12.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Wednesday, October 8th. Chardan Capital raised their price target on shares of Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Senti Biosciences Stock Performance

Shares of NASDAQ SNTI opened at $1.14 on Thursday. The company has a market capitalization of $29.97 million, a P/E ratio of -0.34 and a beta of 2.08. Senti Biosciences has a 52-week low of $1.12 and a 52-week high of $5.10. The company’s 50 day moving average price is $1.83 and its 200-day moving average price is $1.82.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). Analysts forecast that Senti Biosciences will post -14.54 earnings per share for the current year.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.